The hunt for a kidney cancer biomarker reveals two more potential candidates
As the hunt for a reliable biomarker for renal cell [...]
Anlotinib versus sunitinib as first-line treatment for metastatic kidney cancer
The results of a recent phase 2 study to evaluate [...]
Hand-foot syndrome as a predictor of better outcomes in patients treated with sunitinib
A recent study, published in the journal Advances in Medicine [...]
ASCO GU 2019: Nivolumab-ipilimumab survival benefit in advanced kidney cancer
New 30-month survival data from the CheckMate 214 study were [...]
ASCO GU 2019: Avelumab plus axitinib combination superior to sunitinib
The results from the following study were presented at the [...]
ASCO GU 2019: Pembrolizumab plus axitinib versus sunitinib for untreated metastatic RCC
The results from the following study were presented at the [...]
Nivolumab plus ipilimumab combination shows survival benefit for patients with untreated kidney cancer at 30 months
Further survival data has been released from the phase 3 [...]
Four distinct subgroups of clear cell renal cancer identified
Using gene profiling, a recent study published in Cancer Discovery [...]
Surgery may not be the most appropriate frontline treatment for metastatic kidney cancer
Results of the phase 3 SURTIME trial comparing pretreatment with [...]
ESOU 2019: First-line treatment for metastatic renal cell carcinoma – where do we stand?
The following review of the literature for first-line treatment of [...]
